Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

PHOSP-COVID Collaborative Group

Abstract

Background: No effective pharmacological or non-pharmacological interventions exist for patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for COVID-19, identify factors associated with patient-perceived recovery, and identify potential therapeutic targets by describing the underlying inflammatory profiles of the previously described recovery clusters at 5 months after hospital discharge.

Methods: The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study recruiting adults (aged ≥18 years) discharged from hospital with COVID-19 across the UK. Recovery was assessed using patient-reported outcome measures, physical performance, and organ function at 5 months and 1 year after hospital discharge, and stratified by both patient-perceived recovery and recovery cluster. Hierarchical logistic regression modelling was performed for patient-perceived recovery at 1 year. Cluster analysis was done using the clustering large applications k-medoids approach using clinical outcomes at 5 months. Inflammatory protein profiling was analysed from plasma at the 5-month visit. This study is registered on the ISRCTN Registry, ISRCTN10980107, and recruitment is ongoing.

Findings: 2320 participants discharged from hospital between March 7, 2020, and April 18, 2021, were assessed at 5 months after discharge and 807 (32·7%) participants completed both the 5-month and 1-year visits. 279 (35·6%) of these 807 patients were women and 505 (64·4%) were men, with a mean age of 58·7 (SD 12·5) years, and 224 (27·8%) had received invasive mechanical ventilation (WHO class 7-9). The proportion of patients reporting full recovery was unchanged between 5 months (501 [25·5%] of 1965) and 1 year (232 [28·9%] of 804). Factors associated with being less likely to report full recovery at 1 year were female sex (odds ratio 0·68 [95% CI 0·46-0·99]), obesity (0·50 [0·34-0·74]) and invasive mechanical ventilation (0·42 [0·23-0·76]). Cluster analysis (n=1636) corroborated the previously reported four clusters: very severe, severe, moderate with cognitive impairment, and mild, relating to the severity of physical health, mental health, and cognitive impairment at 5 months. We found increased inflammatory mediators of tissue damage and repair in both the very severe and the moderate with cognitive impairment clusters compared with the mild cluster, including IL-6 concentration, which was increased in both comparisons (n=626 participants). We found a substantial deficit in median EQ-5D-5L utility index from before COVID-19 (retrospective assessment; 0·88 [IQR 0·74-1·00]), at 5 months (0·74 [0·64-0·88]) to 1 year (0·75 [0·62-0·88]), with minimal improvements across all outcome measures at 1 year after discharge in the whole cohort and within each of the four clusters.

Interpretation: The sequelae of a hospital admission with COVID-19 were substantial 1 year after discharge across a range of health domains, with the minority in our cohort feeling fully recovered. Patient-perceived health-related quality of life was reduced at 1 year compared with before hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials.

Funding: UK Research and Innovation and National Institute for Health Research.

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Study profile
Figure 2
Figure 2
Patient-perceived recovery at 1 year (A) Compared with patient-perceived recovery at 5 months. (B) Risk factors for being less likely to recover. (C) Compared according to the four clusters. (D) Compared with health-related quality of life (assessed by the EQ-5D-5L utility index). WHO clinical progression scale classes are as follows: 3–4 indicates no continuous supplemental oxygen needed; 5 indicates continuous supplemental oxygen only; 6 indicates continuous positive airway pressure or bi-level positive pressure ventilation or high-flow nasal oxygen; and 7–9 indicates invasive mechanical ventilation or other organ support. The forest plot of the patient and admission characteristics associated with patient-perceived recovery at 1 year used multivariable logistic regression and multiple imputation. EQ-5D-5L score before COVID-19 was retrospectively completed by participants. BMI=body-mass index.
Figure 3
Figure 3
Volcano plots representing multinomial regression association results for comparison of 296 proteins between the four clinical phenotypes Results corrected for age, body-mass index, and number of comorbidities, comparing 296 proteins between very severe physical and mental health impairment and mild physical and mental health impairment clusters (A), severe physical and mental health impairment and mild physical and mental health impairment clusters (B), and moderate physical health impairment with cognitive impairment and mild physical and mental health impairment clusters (C). The red horizontal line represents an unadjusted p

Figure 4

Characteristics associated with the four…

Figure 4

Characteristics associated with the four recovery clusters (A) Patient characteristics, CRP concentration, exercise…

Figure 4
Characteristics associated with the four recovery clusters (A) Patient characteristics, CRP concentration, exercise performance, and symptom count across the four clusters (error bars indicate IQR). (B) Health-related quality of life across the four clusters assessed before hospitalisation (patient estimate), and at 5 months and 1 year after discharge. EQ-5D-5L utility index stratified by cluster and pre-hospital health status assessed retrospectively. Very severe indicates the very severe physical and mental health impairment cluster, severe indicates the severe physical and mental health impairment cluster, moderate with cognitive indicates the moderate physical health impairment with cognitive impairment cluster, and mild indicates the mild physical and mental health impairment cluster. BMI=body-mass index. CRP=mean C-reactive protein concentration assessed at 1 year. IMV=invasive mechanical ventilation. ISWT=incremental shuttle walk test distance percentage predicted assessed at 1 year. *Median number of symptoms at 1 year.
Figure 4
Figure 4
Characteristics associated with the four recovery clusters (A) Patient characteristics, CRP concentration, exercise performance, and symptom count across the four clusters (error bars indicate IQR). (B) Health-related quality of life across the four clusters assessed before hospitalisation (patient estimate), and at 5 months and 1 year after discharge. EQ-5D-5L utility index stratified by cluster and pre-hospital health status assessed retrospectively. Very severe indicates the very severe physical and mental health impairment cluster, severe indicates the severe physical and mental health impairment cluster, moderate with cognitive indicates the moderate physical health impairment with cognitive impairment cluster, and mild indicates the mild physical and mental health impairment cluster. BMI=body-mass index. CRP=mean C-reactive protein concentration assessed at 1 year. IMV=invasive mechanical ventilation. ISWT=incremental shuttle walk test distance percentage predicted assessed at 1 year. *Median number of symptoms at 1 year.

References

    1. Johns Hopkins University Coronavirus resource centre.
    1. UK Government Coronavirus (COVID-19) in the UK.
    1. Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9:1275–1287.
    1. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–232.
    1. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747–758.
    1. Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021;2
    1. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021;6
    1. National Institute for Health and Care Excellence COVID-19 rapid guideline: managing the long-term effects of COVID-19. Updated November, 2021.
    1. WHO A clinical case definition of post COVID-19 condition by a Delphi consensus. Oct 6, 2021.
    1. Kaufman L, Rousseeuw PJ. Finding groups in data: an introduction to cluster analysis. John Wiley & Sons, Inc; New Jersey: 2008. Clustering large applications (Program CLARA) pp. 126–163.
    1. Fu W, Liu Y, Liu L, et al. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. EClinicalMedicine. 2020;27
    1. Tserel L, Jõgi P, Naaber P, et al. Long-Term Elevated inflammatory protein levels in asymptomatic SARS-CoV-2 infected individuals. Front Immunol. 2021;12
    1. Fraser DD, Patterson EK, Slessarev M, et al. Endothelial injury and glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit Care Explor. 2020;2:e0194.
    1. Laudanski K, Jihane H, Antalosky B, et al. Unbiased analysis of temporal changes in immune serum markers in acute COVID-19 infection with emphasis on organ failure, anti-viral treatment, and demographic characteristics. Front Immunol. 2021;12
    1. Hettwer S, Dahinden P, Kucsera S, et al. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol. 2013;48:69–75.
    1. Dhaeze T, Tremblay L, Lachance C, et al. CD70 defines a subset of proinflammatory and CNS-pathogenic TH1/TH17 lymphocytes and is overexpressed in multiple sclerosis. Cell Mol Immunol. 2019;16:652–665.
    1. Griffith DM, Vale ME, Campbell C, Lewis S, Walsh TS. Persistent inflammation and recovery after intensive care: a systematic review. J Crit Care. 2016;33:192–199.
    1. Fernández-de-Las-Peñas C, Guijarro C, Plaza-Canteli S, Hernández-Barrera V, Torres-Macho J. Prevalence of post-COVID-19 cough one year after SARS-CoV-2 infection: a multicenter study. Lung. 2021;199:249–253.
    1. Maestre-Muñiz MM, Arias Á, Mata-Vázquez E, et al. Long-term outcomes of patients with coronavirus disease 2019 at one year after hospital discharge. J Clin Med. 2021;10
    1. Latronico N, Peli E, Calza S, et al. Physical, cognitive and mental health outcomes in 1-year survivors of COVID-19-associated ARDS. Thorax. 2021 doi: 10.1136/thoraxjnl-2021-218064. published online Sept 29.
    1. Dowdy DW, Eid MP, Dennison CR, et al. Quality of life after acute respiratory distress syndrome: a meta-analysis. Intensive Care Med. 2006;32:1115–1124.
    1. Parry SM, Nalamalapu SR, Nunna K, et al. Six-minute walk distance after critical illness: a systematic review and meta-analysis. J Intensive Care Med. 2021;36:343–351.
    1. Whitaker M, Elliott J, Chadeau-Hyam M, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508 707 people. medRxiv. 2021 doi: 10.1101/2021.06.28.21259452. published online July 3. (preprint).
    1. Blomberg B, Mohn KG, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607–1613.
    1. Wynberg E, van Willigen HDG, Dijkstra M, et al. Evolution of COVID-19 symptoms during the first 12 months after illness onset. Clin Infect Dis. 2021 doi: 10.1093/cid/ciab759. published online Sept 2.
    1. Thompson EJ, Williams DM, Walker AJ, et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv. 2021 doi: 10.1101/2021.06.24.21259277. published online July 10.
    1. UK Office of National Statistics COVID-19.
    1. Boscolo-Rizzo P, Guida F, Polesel J, et al. Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19) Int Forum Allergy Rhinol. 2021;11:1685–1688.
    1. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626–631.
    1. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3
    1. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752–1760.
    1. Evans RA, Singh SJ. Minimum important difference of the incremental shuttle walk test distance in patients with COPD. Thorax. 2019;74:994–995.
    1. Nolan CM, Delogu V, Maddocks M, et al. Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study. Thorax. 2017;73:680–682.
    1. Parreira VF, Janaudis-Ferreira T, Evans RA, Mathur S, Goldstein RS, Brooks D. Measurement properties of the incremental shuttle walk test: a systematic review. Chest. 2014;145:1357–1369.
    1. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated international task force. Eur Respir J. 2020;56
    1. Martin A, Naunton M, Kosari S, Peterson G, Thomas J, Christenson JK. Treatment guidelines for PTSD: a systematic review. J Clin Med. 2021;10
    1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.
    1. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021;9:773–785.

Source: PubMed

3
Abonnieren